

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010890 A1

- (51) International Patent Classification⁷: **A61C 8/00**, (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/SE2003/001109
- (22) International Filing Date: 26 June 2003 (26.06.2003)
- (25) Filing Language: Swedish
- (26) Publication Language: English
- (30) Priority Data: 0202318-2 25 July 2002 (25.07.2002) SE
- (71) Applicant (*for all designated States except US*): NOBEL BIOACARE AB (publ) [SE/SE]; Box 5190, S-402 26 Göteborg (SE).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): HALL, Jan [SE/SE]; Stabbegatan 2A, S-416 80 Göteborg (SE).
- (74) Agent: OLSSON, Gunnar; Nobel Biocare AB (publ), Box 5190, S-402 26 Göteborg (SE).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ARRANGEMENT OF TWO OR MORE IMPLANTS PROVIDED WITH GROWTH-STIMULATING SUBSTANCE(S)



(57) Abstract: Two or more implants (8, 9, 10) are arranged in succession in the jaw bone (1) and bear or comprise growth-stimulating substances (25), here called GSS, which, as a function of secretion of body fluid at the implants, are intended to be released and form new bone (11-15) around the implants. The implants are designed to work with a release process for GSS, permitting a leveling-out effect along the extent of the jaw bone in the horizontal and/or vertical direction and/or a level-raising effect in the vertical direction. In this way it is possible to achieve optimum positions for the implants without the risk of reduced stability and/or compromised esthetics.